Nilotinib Patent Expiration
Nilotinib was first introduced by Cycle Pharmaceuticals Ltd
Nilotinib Patents
Given below is the list of patents protecting Nilotinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cavhanza | US11559485 | Orally Disintegrating Tablet Comprising Amorphous Solid Dispersion Of Nilotinib | Apr 30, 2041 | Cycle |
| Cavhanza | US11389450 | Amorphous Nilotinib Microparticles And Uses Thereof | Jan 29, 2041 | Cycle |
| Cavhanza | US12016861 | Amorphous Nilotinib Microparticles And Uses Thereof | Jan 29, 2041 | Cycle |
| Cavhanza | US12029740 | Amorphous Nilotinib Microparticles And Uses Thereof | Jan 29, 2041 | Cycle |
Nilotinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Nilotinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
